OWENS v. PFIZER, INC., et al

Track this case

Case overview

Case Number:

2:02-cv-01390

Court:

New Jersey

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Madeline Cox Arleo

Firms

Companies

Sectors & Industries:

October 29, 2019
Allergan's $750M Deal Among Pharma's Top Antitrust Payouts

A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.
October 21, 2014
Special Master To Helm Walgreen Fee Fight In Pfizer MDL

A New Jersey federal judge overseeing multidistrict litigation over whether Pfizer Inc. conspired to bar competition for its epilepsy treatment Neurontin and promoted off-label uses on Monday appointed a special master to handle a dispute over attorneys' fees between opt-out plaintiff Walgreen Co. and class counsel.
September 15, 2014
Walgreen Blasts 'Chutzpah' Of Attys' Fee Bid In Pfizer MDL

Walgreen Co. urged a New Jersey federal court Friday to deny class counsel a cut of the fees from Walgreen's antitrust settlement with Pfizer Inc. over its epilepsy treatment Neurontin, saying class counsel in the multidistrict litigation actively worked against Walgreen after it opted out of the class.
April 21, 2014
Pfizer Strikes $190M Deal To Settle Neurontin Antitrust MDL

Pfizer Inc. on Monday agreed to pay $190 million to settle a class action coursing through New Jersey federal court alleging that the drug giant conspired to bar competition for its epilepsy treatment Neurontin and promoted off-label uses, signaling an end to more than a decade's worth of contentious antitrust litigation.
August 08, 2013
Pfizer Can't Escape Neurontin Antitrust MDL

A New Jersey federal judge on Thursday refused Pfizer Inc.'s bid to squash a multidistrict litigation accusing the pharmaceutical giant of conspiring to bar competition for its epilepsy treatment Neurontin and promoting off-label uses, saying there are many factual disputes that must be resolved.
December 03, 2012
Plaintiffs Lose Doc Request In Pfizer Epilepsy Drug MDL

A New Jersey federal judge on Friday refused to release documents from patent litigation over Pfizer's Neurontin to a class of plaintiffs accusing it of inhibiting the epilepsy treatment's generic rivals, saying their allegations weren't enough to overcome attorney-client privilege.
July 07, 2011
Pfizer Dodges More Sanctions In Neurontin Antitrust MDL

A magistrate judge refused Tuesday to sanction Pfizer Inc. by striking its denial that it promoted off-label uses of epilepsy drug Neurontin, the latest in a New Jersey multidistrict litigation claiming the drugmaker used patent litigation to delay generic competition.
June 10, 2011
Pfizer Sanctions Affirmed In Neurontin Antitrust MDL

A New Jersey federal judge on Thursday upheld sanctions against Pfizer Inc. for a witness testimony violation in a class action that accuses the pharmaceutical giant of using patent litigation to delay generic competition for epilepsy drug Neurontin.
February 08, 2011
Pfizer Appeals Sanctions In Neurontin Antitrust Action

Pfizer Inc. has appealed a magistrate judge's order sanctioning the company for a witness testimony violation in a class action that accuses the pharmaceutical giant of using patent litigation to delay generic competition for epilepsy drug Neurontin.
January 26, 2011
Pfizer Sanctioned Over Shoddy Witness Testimony

A federal court has sanctioned Pfizer Inc. for a witness testimony violation and also certified a class of direct purchasers that accuses the pharmaceutical giant and a subsidiary of using patent litigation to delay generic competition for epilepsy drug Neurontin.